Evidence map›Paper›PMID 19751498›Full record

ArticleBMC genomics2009

Transcriptome analysis of the responses of Staphylococcus aureus to antimicrobial peptides and characterization of the roles of vraDE and vraSR in antimicrobial resistance.

Milla Pietiäinen, Patrice François, Hanne-Leena Hyyryläinen, Manuela Tangomo, Vera Sass, Hans-Georg Sahl, Jacques Schrenzel, Vesa P Kontinen

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Crosstalk involving two-component systems inJournal of bacteriology · 2024
    Review
  5. Article
  6. Article
  7. Biocontrol and Action Mechanism ofFrontiers in microbiology · 2022
    Article
  8. Newly discoveredADMET & DMPK · 2022
    Review
  9. The Role ofFrontiers in microbiology · 2021
    Article
  10. Article
  11. Article
  12. Review
  13. The Staphylococcal Cell Wall.Microbiology spectrum · 2019
    Review
  14. Frontiers in cellular and infection microbiology · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Milla PietiäinenAntimicrobial Resistance Unit, Department of Infectious Disease Surveillance and Control, National Institute for Health and Welfare (THL), PL 30, 00271 Helsinki, Finland.
Patrice François
Hanne-Leena Hyyryläinen
Manuela Tangomo
Vera Sass
Hans-Georg Sahl
Jacques Schrenzel
Vesa P Kontinen
Finnish Institute for Health and Welfare · FIUniversity Hospital of Geneva · CHUniversity of Bonn · DEUniversity of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnderstanding how pathogens respond to antimicrobial peptides, and how this compares to currently available antibiotics, is crucial for optimizing antimicrobial therapy. Staphylococcus aureus has several known resistance mechanisms against human cationic antimicrobial peptides (CAMPs). Gene expression changes in S. aureus strain Newman exposed to linear CAMPs were analyzed by DNA microarray. Three antimicrobial peptides were used in the analysis, two are derived from frog, temporin L and dermaseptin K4-S4(1-16), and the ovispirin-1 is obtained from sheep.

resultsThe peptides induced the VraSR cell-wall regulon and several other genes that are also up-regulated in cells treated with vancomycin and other cell wall-active antibiotics. In addition to this similarity, three genes/operons were particularly strongly induced by the peptides: vraDE, SA0205 and SAS016, encoding an ABC transporter, a putative membrane-bound lysostaphin-like peptidase and a small functionally unknown protein, respectively. Ovispirin-1 and dermaseptin K4-S4(1-16), which disrupt lipid bilayers by the carpet mechanism, appeared to be strong inducers of the vraDE operon. We show that high level induction by ovispirin-1 is dependent on the amide modification of the peptide C-terminus. This suggests that the amide group has a crucial role in the activation of the Aps (GraRS) sensory system, the regulator of vraDE. In contrast, temporin L, which disrupts lipid bilayers by forming pores, revealed a weaker inducer of vraDE despite the C-terminal amide modification. Sensitivity testing with CAMPs and other antimicrobials suggested that VraDE is a transporter dedicated to resist bacitracin. We also showed that SA0205 belongs to the VraSR regulon. Furthermore, VraSR was shown to be important for resistance against a wide range of cell wall-active antibiotics and other antimicrobial agents including the amide-modified ovispirin-1, bacitracin, teicoplanin, cefotaxime and 10 other beta-lactam antibiotics, chlorpromazine, thioridazine and EGTA.

conclusionDefense against different CAMPs involves not only general signaling pathways but also CAMP-specific ones. These results suggest that CAMPs or a mixture of CAMPs could constitute a potential additive to standard antibiotic treatment.

Indexed as

Gene Expression ProfilingAmphibian ProteinsAnimalsAntimicrobial Cationic PeptidesATP-Binding Cassette TransportersBacterial ProteinsCell WallDNA-Binding ProteinsDrug Resistance, BacterialGene Expression Regulation, BacterialMicrobial Sensitivity TestsMutationOligonucleotide Array Sequence AnalysisOperonProteinsRegulonAmphibian ProteinsAntimicrobial Cationic PeptidesATP-Binding Cassette TransportersBacterial ProteinsdermaseptinDNA-Binding ProteinsovispirinProteinsRNA, BacterialtemporinVirulence FactorsVraR protein, Staphylococcus aureusVraS protein, Staphylococcus aureus

Identifiers

PMID19751498
PMCPMC2748101
OpenAlexW1278288180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.